HUP9901039A2 - Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines - Google Patents

Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines

Info

Publication number
HUP9901039A2
HUP9901039A2 HU9901039A HUP9901039A HUP9901039A2 HU P9901039 A2 HUP9901039 A2 HU P9901039A2 HU 9901039 A HU9901039 A HU 9901039A HU P9901039 A HUP9901039 A HU P9901039A HU P9901039 A2 HUP9901039 A2 HU P9901039A2
Authority
HU
Hungary
Prior art keywords
pipe
expression
yeast
outer membrane
belonging
Prior art date
Application number
HU9901039A
Other languages
Hungarian (hu)
Inventor
Mikhail Donets
Shu-Mei Liang
Francis Michon
Conceicao Minetti
Maryellen Polvino-Bodnar
Joseph Y. Tai
Ming-Der Wang
Original Assignee
North American Vaccine, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine, Inc. filed Critical North American Vaccine, Inc.
Publication of HUP9901039A2 publication Critical patent/HUP9901039A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

A találmány tárgyát képezik eljárásők Neisseria meningitidis-bőlszármazó, annak külső membránján elhelyezkedő, B-csőpőrtba tartőzópőrinfehérje expresszáltatására rekőmbináns élesztőgazdasejtekben. Atalálmány tárgyát képezik tővábbá A-csőpőrtba tartőzó meningőkőkkűsz-pőliszacharid-antigént (GAMP), B-csőpőrtba tartőzó meningőkőkkűsz-pőliszacharid-antigént (GBMP) és C-csőpőrtba tartőzó meningőkőkkűsz-pőliszacharid-antigént (GOMP), valamint gyógyászatilag elfőgadhatóhőrdőzót tartalmazó vakcinák. A találmány tárgyát képezik tővábbáeljárásők imműnválasz kiváltására emlősben, amely sőrán a vakcinátimműnválasz emlősben való kiváltására elegendő mennyiségben adják be.A találmány szerinti megőldás alkalmas a B-csőpőrtba tartőzómeningőkőkkűszők pőrinfehérjéinek, előnyösen a 3. ősztályba tartőzópőrinfehérjéknek élesztőben történő expesszálására. ŕThe subject of the invention are procedures for the expression of powdery protein originating from Neisseria meningitidis, located on its outer membrane and belonging to the B-tubular pore, in recombinant yeast host cells. The object of the inventory is the more dive-pipe-pipe-pipe-palaschcharide antigen (GAMP), mening hubs-peppercaride antigen (GBMP) and C-pipe mening pipe-pipe-pipe-pipe-pipe male vaccines containing Á. The subject of the invention are further methods for inducing an immune response in a mammal, which are usually administered in a quantity sufficient to induce a vaccine immune response in a mammal. The solution according to the invention is suitable for the expression of powder proteins of meningococcal cells belonging to the B-tubule, preferably powder proteins belonging to class 3, in yeast. ŕ

HU9901039A 1996-02-01 1997-01-31 Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines HUP9901039A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1097296P 1996-02-01 1996-02-01
US2044096P 1996-06-13 1996-06-13

Publications (1)

Publication Number Publication Date
HUP9901039A2 true HUP9901039A2 (en) 1999-07-28

Family

ID=26681820

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901039A HUP9901039A2 (en) 1996-02-01 1997-01-31 Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines

Country Status (9)

Country Link
EP (1) EP0877816A1 (en)
JP (1) JP2001508758A (en)
KR (1) KR19990082265A (en)
AU (1) AU2115897A (en)
HU (1) HUP9901039A2 (en)
IL (1) IL125420A0 (en)
NO (1) NO983474L (en)
PL (1) PL328096A1 (en)
WO (1) WO1997028273A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1272062A (en) 1997-07-17 2000-11-01 北美疫苗公司 Immunogenic conjugates comprising group meningococcal porin and an i (H. influenzae) polysaccharide
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
JP4524816B2 (en) * 1998-07-06 2010-08-18 東ソー株式会社 IL-6 receptor / IL-6 direct fusion protein
EP1094081B1 (en) * 1998-07-06 2005-09-21 Tosoh Corporation Fused protein with direct bond of il-6-receptor to il-6
GB9818004D0 (en) * 1998-08-18 1998-10-14 Smithkline Beecham Biolog Novel compounds
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
HUP0201220A3 (en) 1999-05-13 2004-07-28 Wyeth Holdings Corp Madison Adjuvant combination formulations
CA2373236C (en) 1999-05-19 2014-08-26 Chiron S.P.A. Combination neisserial compositions
EP1069133A1 (en) 1999-07-13 2001-01-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neisseria meningitidis compounds and anti-infection applications thereof
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP1234039A2 (en) * 1999-11-29 2002-08-28 Chiron Spa 85kDa NEISSERIAL ANTIGEN
EP2275129A3 (en) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
WO2001064920A2 (en) 2000-02-28 2001-09-07 Chiron Spa Hybrid expression of neisserial proteins
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
ATE492288T1 (en) 2002-10-11 2011-01-15 Novartis Vaccines & Diagnostic POLYPEPTIDE VACCINES FOR BROAD PROTECTION AGAINST HYPERVIRULENT MENINGOCOCCAL LINES
JP4827726B2 (en) 2003-01-30 2011-11-30 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Injectable vaccine against multiple meningococcal serogroups
JP2006262846A (en) * 2005-03-25 2006-10-05 Niigata Bio Research Park Kk Method for synthesizing and purifying 2-deoxy-scyllo-inosose with yeast and obtained 2-deoxy-scyllo-inosose
KR100919704B1 (en) * 2007-09-12 2009-10-06 한국생명공학연구원 An Effective Method for Expressing and Secreting Recombinant Proteins in Yeast
JP2011116658A (en) * 2008-03-13 2011-06-16 Chemo-Sero-Therapeutic Research Inst Manufacturing method of medicine for swine atrophic rhinitis
WO2015073801A1 (en) * 2013-11-14 2015-05-21 Duke University Tetanus toxoid and ccl3 improve dc vaccines
CN106146679B (en) * 2015-04-23 2019-02-01 中国医学科学院医学生物学研究所 A kind of method of purification of bacterial capsular polysaccharide
WO2017115323A2 (en) * 2015-12-30 2017-07-06 Dsm Ip Assets B.V. Partial enzymatic hydrolysis of triacylglycerols
CN114555812A (en) * 2019-04-17 2022-05-27 非凡食品有限公司 Materials and methods for protein production

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5268273A (en) * 1990-12-14 1993-12-07 Phillips Petroleum Company Pichia pastoris acid phosphatase gene, gene regions, signal sequence and expression vectors comprising same
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis

Also Published As

Publication number Publication date
NO983474L (en) 1998-09-30
WO1997028273A1 (en) 1997-08-07
IL125420A0 (en) 1999-03-12
PL328096A1 (en) 1999-01-04
JP2001508758A (en) 2001-07-03
NO983474D0 (en) 1998-07-28
KR19990082265A (en) 1999-11-25
EP0877816A1 (en) 1998-11-18
AU2115897A (en) 1997-08-22

Similar Documents

Publication Publication Date Title
HUP9901039A2 (en) Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines
AU657487B2 (en) Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations
WO1990006696A3 (en) Meningococcal class 1 outer-membrane protein vaccine
EP1006782A4 (en) Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid
DK1002110T3 (en) Immune response to HPV antigens induced by compositions comprising an HPV antigen and a stress protein or expression vector capable of expressing these proteins
DE69529219T2 (en) HELICOBACTER PROTEINS AND VACCINES
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
AU7481498A (en) Immuno-reactive peptide ctl epitopes of human cytomegalovirus
NO912825D0 (en) PROCEDURE FOR THE PREPARATION OF COCONJUGATE VACCINES INCLUDING IMMUNOGENIC PROTEIN, HIV RELATED PEPTIDES AND ANIONIC GROUPS.
DK1267924T3 (en) Immunotherapeutic methods and compositions
AU1800597A (en) Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
MXPA03005032A (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens.
ATE262539T1 (en) IMMUNOREACTIVE PEPTIDE CTL EPITOPES OF HUMAN CYTOMEGALOVIRUS
FI924457A0 (en) COMPOSITION OR BEHANDLINGSFOERFARANDE FOER LUNGINFLAMMATION I DJUR
DE69933875D1 (en) PROTEIN ADMINISTRATION SYSTEM USING SIMILAR PARTICLES TO HUMAN PAPILLOMA VIRUS.
EP0327180A3 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
DK0952771T3 (en) New Saponin Preparations and Uses thereof
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
MY126769A (en) Dna sequence encoding the specific and antigenic outer membrane protein of salmonella typhi
Czerkinsky et al. Lymphoid cell populations dynamics and the mucosal immune response in humans
ES2017258A6 (en) Vaccine against melanoma
CA2007248A1 (en) Meningococcal class 1 outer-membrane protein vaccine
Czerkinsky et al. Departments of Medical Microbiology, Medicine, Clinical Immunology and Oral Pathology, University of Göteborg and Kabi Vitrum AB, Stockholm, Sweden
NZ334582A (en) Polyprotein construct of a papillomavirus
MX9700215A (en) Helicobacter proteins and vaccines.